Kyverna Therapeutics, Inc. financial data

Symbol
KYTX on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
5980 Horton Street, Suite 550, Emeryville, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 27, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.22K %
Debt-to-equity 10.5 %
Return On Equity -40.4 % -171%
Return On Assets -36.5 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 43.2M shares +0.23%
Common Stock, Shares, Outstanding 43.2M shares +3357%
Entity Public Float 222M USD
Weighted Average Number of Shares Outstanding, Basic 38.3M shares +5591%
Weighted Average Number of Shares Outstanding, Diluted 38.3M shares +5591%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 112M USD +125%
General and Administrative Expense 30.1M USD +141%
Operating Income (Loss) -143M USD -129%
Nonoperating Income (Expense) 15.1M USD +642%
Net Income (Loss) Attributable to Parent -127M USD -111%
Earnings Per Share, Basic -3.33 USD/shares +96.3%
Earnings Per Share, Diluted -3.33 USD/shares +96.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 96.6M USD +179%
Marketable Securities, Current 189M USD +727%
Cash, Cash Equivalents, and Short-term Investments 286M USD
Assets, Current 291M USD +379%
Property, Plant and Equipment, Net 3.35M USD +43.9%
Operating Lease, Right-of-Use Asset 6.47M USD -0.4%
Other Assets, Noncurrent 2.84M USD -15.5%
Assets 305M USD +305%
Accounts Payable, Current 4.62M USD +6.1%
Liabilities, Current 33.8M USD +70%
Operating Lease, Liability, Noncurrent 4.16M USD -20.6%
Other Liabilities, Noncurrent 296K USD
Liabilities 38.1M USD +46.3%
Accumulated Other Comprehensive Income (Loss), Net of Tax 105K USD +2525%
Retained Earnings (Accumulated Deficit) -264M USD -93.7%
Stockholders' Equity Attributable to Parent 267M USD
Liabilities and Equity 305M USD +305%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -25.5M USD -123%
Net Cash Provided by (Used in) Financing Activities 338M USD
Net Cash Provided by (Used in) Investing Activities -123M USD -1000%
Common Stock, Shares Authorized 490M shares +249%
Common Stock, Shares, Issued 43.2M shares +3357%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 190M USD +9137%
Interest Paid, Excluding Capitalized Interest, Operating Activities 44K USD 0%
Deferred Tax Assets, Valuation Allowance 65.6M USD +106%
Deferred Tax Assets, Gross 67.5M USD +99.6%
Operating Lease, Liability 7.32M USD
Payments to Acquire Property, Plant, and Equipment 543K USD +1839%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -127M USD -111%
Lessee, Operating Lease, Liability, to be Paid 8.06M USD
Property, Plant and Equipment, Gross 7.02M USD +45.8%
Operating Lease, Liability, Current 3.16M USD +60.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 4.05M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 3.56M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure +12.5%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 734K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 446K USD
Deferred Tax Assets, Operating Loss Carryforwards 17.2M USD +59.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares
Unrecognized Tax Benefits 19.5M USD +132%
Operating Lease, Payments 3.07M USD +28.9%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 482K USD +22.3%
Deferred Tax Assets, Net of Valuation Allowance 1.88M USD -7.73%
Share-based Payment Arrangement, Expense 8.36M USD +276%
Interest Expense 39K USD -15.2%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares